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A B S T R A C T
We evaluated the role of human gastric pentadecapeptide BPC 157 in corneal epithelial defects healing in rats. 48
rats, in 4 groups (N=12). Total debridement of corneal epithelium preformed unilaterally and lesions stained and pho-
tographed. Animals medicated as follows: distilled water (control group) or BPC 157 2pg/ml, 2ng/ml, 2µg/ml, 2
drops/rat eye started immediately after injury induction, every 8 hours up to 40 hours (i.e., at 0, 8, 16, 24, 32, 40 h).
Lesions were photographed before application or sacrifice (at 48 h). Defect area was analyzed using a special program.
Through 48 hour period a steady recovery is noted in controls. Recovery was markedly accelerated in eyes on µg- or
ng-topical regimen of BPC 157 (p<0.05). Of note, unlike control lesion present also after 48h, these lesions disappeared
already following 40 h (µg) or 48 h (ng) post-injury. BPC 157 was shown to be effective in promoting corneal defects
healing in rats. Results were dose dependent.
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Introduction
Epidermal growth factor (EGF)1 and nerve growth
factor (NGF)2 promote corneal epithelial healing. How-
ever, most protein growth factors that might improve
the healing are rapidly metabolized by the organism.
Besides, for full effect, peptidergic agents frequently ne-
cessitate carriers’ activity or addition. However, all spe-
cial regimens remain inappropriate for routine use, and
search for new agents for regular use is fully justified.
Our focus is gastric pentadecapeptide BPC 157, cur-
rently in clinical trials for inflammatory bowel disease
(PLD-116, Pliva). Recently, as a solution, it also stimu-
lates corneal epithelial healing3. Therefore, we remove
the entire epithelium, and this study further investi-
gates the healing in severely impaired condition.
Possible recovery of completely denudated rat cornea
is studied due to its healing effects on various tissues
given systemically and/or locally4–10. Initially, BPC 157
opposes a variety of gastrointestinal lesions including
stress-ulcer and thermal injury-gastric lesions8,10, and
thereafter it cures, besides corneal3, different wounds
(i.e., skin6, colon-colon anastomosis10, deep skin burn4,
segmental osteoperiosteal bone defects5). Also, it modu-
lates NO-synthesis6. This may directly affect repair of
connective tissues6, as an ordered multistage process in-
volving inflammation.
Besides, this gastric pentadecapeptide BPC 157 li-
kely controls functions of collagen fragments5. Likewise,
it has special relation over bone morphogenetic proteins
(BMPs)11. It has high stability and shows no degrada-
tion in human gastric juice even for 24 h (unlike rapidly
degraded h-TGF, and h-EGF)9. Finally, no carrier is
used in previous4–10 and present studies. Together, this
stable pentadecapeptide highly resistant to otherwise
inescapable degradation of peptides, presented with heal-
ing potential of its own4–10, may be suitable for therapy
of complex structures such as completely denudated rat
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Slovenia) is a partial of sequence of human gastric juice
protein BPC, freely soluble in water at pH 7.0 and in sa-
line. It was prepared as described before4–10. Peptide
with 99% (HPLC) purity (1-des-Gly peptide as impu-
rity), dissolved in distilled water was used in all of the
experiments4–10.
Experimental procedure
Male Wistar Albino rats, 200 g body weight, fed a
stock diet with water ad libitum randomly assigned are
used in all of the experiments. All of the experiments
are approved by local Ethic Committee. Under deep ane-
sthesia (ketamine Ketalar, 50 mg/kg i.p.) topical ane-
sthetic tetracaine (2 drops; Tetrakain, Pliva, Croatia) to
further inhibit possible eyelids reflex and to soften the
corneal epithelium is given prior total debridement of
corneal epithelium as described before12. Briefly, abra-
sion is made with the scalpel blade unilaterally under
operating microscope, and the lesions stained with stan-
dard fluorescein solution for better visualization and
photographed with a magnification camera.
Medication
Medication (distilled water for control group) or BPC
157 2pg/ml, 2ng/ml, 2µg/ml, 2 drops/rat eye) is started
immediately after injury induction, every 8 hours up to
40 hours (i.e., at 0 h, 8 h,16 h, 24 h, 32 h, and 40 h).
Assessment of lesions and data analysis
The healing process was monitored by photography
of the fluorescein stained cornea before application or
sacrifice (48 hours following lesions induction). The ero-
sion area (stained green) was determined by morpho-
metrical analysis using a special program SFORM of
VAMSTECH-Software Company (VAMSTECH, Zagreb,
Croatia). The size of the de-eptihelized area is expressed
as a percentage of the total corneal area.
Statistical analysis
The difference among groups was analyised with
ANOVA (Analysis of Variance) and was considered sig-
nificant at p < 0.05. The in-beetween group comparison
was analysied with Tukey HSD test and was considered
significant at p < 0.05.
Results
Total debridement of corneal epithelium leads to
completely denudated cornea, confirmed by histological
examination, and a complete fluorescein stained area in
all rats before therapy. Through 48 hour period a steady
recovery is noted in controls. However, a significant pro-
portion (i.e. 15%) still remains green.
Compared with the control values, recovery is mark-
edly accelerated in BPC treated groups (Figure 1). Since
the earliest interval completely denudated rat corneas
presented with positive outcome following µg- or ng-top-
ical regimen of pentadecapeptide BPC 157. Of note, un-
like control lesion present also after 48 hours, these le-
sions disappear already following 40 hours (µg) or 48
hours (ng) post-injury. (Figures 2–7).
Discussion
Regardless the general knowledge that the healing is
always the same, corneal transparency provides particu-
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Fig. 1. BPC given in eye drops (µg and ng concentrations) immediately after injuries were induced, and in 8 hour intervals signifi-
cantly improved corneal epithelial defects healing when compared to controls and pg BPC treated groups. (* p<0.05).
Fig. 2. Characteristic eye presentation in controls 8 hours after
the entire epithelium removal. The defect area was stained green
by flourescein while the 10 % of the remaining corneal surface
showed spontaneous marginal epithelial recovery.
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lar limitation. Namely, transparency is essential for the
maintenance of visual function. Consequently, activated
healing after anatomic barrier disruption presenting
with remodeling processes predisposes the tissue to
stromal ulceration and/or causes stromal opacification.
Ultimately, the otherwise positive healing process para-
doxically leads to irreversible visual deficit2. The trans-
parency necessitates the flawless integrity of all its com-
ponents: epithelium, stoma and endothelium2. This
obviously provides particular requests to an agent sup-
pose to accelerate complex corneal healing processes.
Unlike our previous study confined to only small corneal
lesion3, the entire epithelium is removed, and the total
cornea denudated. Like in the case of other tissues heal-
ing, pentadecapeptide BPC 157 alone (i.e., without any
carrier) accelerates repair of corneal lesion. Therefore,
since it accelerates also complex corneal healing and
preserves transparency, it purposefully accelerates the
healing process, presenting with no limitation due to
angiogenesis shown in other models. Since acceleration
is noted in different conditions (i.e., early phase imme-
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Fig. 4. Characteristic eye presentation in controls 32 hours after
the entire epithelium removal. The defect area was stained green
by flourescein while the 70 % of the remaining corneal surface
showed spontaneous epithelial recovery coming from the edges.
Fig. 5. Characteristic eye presentation in BPC 157 treated eye
32 hours after the entire epithelium removal. The defect area
was stained green by flourescein while the 95 % of the corneal
surface showed promoted epithelial recovery by BPC 157 admi-
nistered in µg concentration solution. The defect area was sig-
nificantly smaller compared to controls.
Fig. 6. Characteristic eye presentation in controls 40 hours after
the entire epithelium removal. 77 % of the corneal surface showed
spontaneous epithelial recovery.
Fig. 7. Characteristic eye presentation in BPC 157 treated eye
40 hours after the entire epithelium removal. The corneal surface
was completely healed showing a µg BPC 157 healing effect unlike
controls which are still presenting with epithelium defect.
Fig. 3. Characteristic eye presentation in BPC 157 treated eye 8
hours after the entire epithelium removal. The defect area was
stained green by flourescein while the 15 % of the remaining
corneal surface showed promoted marginal epithelial recovery
by BPC 157 administered in µg concentration solution. The de-
fect area was significantly smaller compared to controls.
U:\coll-antropolo\coll-antro-1-2005\lazic.vp
17. lipanj 2005 10:26:17
Color profile: Disabled
Composite  150 lpi at 45 degrees
diate application following injury, as well as delayed
phase application following injury), pentadecapeptide
BPC 157 presented with a healing effect of its own.
BPC 157 could be efficient also in vivo as a growth-
-regulating factor. Besides, BPC 157 may alleviate all
sequence of the healing events since these processes im-
proved over control and/or standard agents values had
already been shown in pentadecapeptide BPC 157 stu-
dies4–10. Specifically, besides angiogenesis in Szabo’s an-
giogenesis model (i.e., synthetic sponge implantation8,
evidenced are advanced collagen, reticulin and blood
vessels formation, increased tensile breaking force (skin
incision wounds6, deep partial thickness skin burns4,
raised bursting pressure (colon-colon anastomoses10. An
advanced healing in special and complex conditions is
also shown (i.e., healing of segmental osteoperiosteal
bone defect that otherwise does not heal5. Therefore, the
prominent improvement of otherwise delayed healing of
completely denudated rat cornea is within the frame-
work of its healing effect. Therefore, since it accelerates
also complex corneal healing and preserves transpa-
rency, it purposefully accelerates the healing process,
presenting with no limitation due to angiogenesis shown
in other models. Since acceleration is noted in different
conditions (i.e., early phase immediate application fol-
lowing injury, as well as delayed phase applications
following injury), pentadecapeptide BPC 157 presented
with a healing effect of its own.
Corneal conditions may provide particular problems
related to generally impair medication accessibility, and
therapeutic efficacy. However, as mentioned, pentade-
capeptide BPC 157 had been already seen to be effective
besides given systemically (i.p. or i.m.)4,5, also locally in
alike complex structures healing. The impaired healing
presented with deep partial thickness skin burn4, non-
-union model5 is consistently positively affected by local
pentadecapeptide BPC 157 administration. The repair
of completely denudated cornea is accelerated without
carrier addition, like other healing effects4–10, along
with suggested unusual stability, and high resistance to
otherwise highly degrading media4,9.
Human gastric pentadecapeptide BPC157 when ap-
plied locally significantly speeds up the corneal epithe-
lial defects healing in rats. The results were dose de-
pendent.
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GASTRI^NI PENTADECAPEPTID BPC 157 UBRZAVA CIJELJENJE RO@NI^NIH EPITELNIH
EROZIJA U [TAKORA
S A @ E T A K
Istra`ivan je utjecaj humanog gastri~nog pentadekapeptida BPC 157 na zacijeljivanje ro`ni~nih epitelnih defe-
kata u {takora. Denudacija ro`ni~nog epitela u~injena je unilateralno u 48 {takora, u ~etiri grupe (N=12), te su lezije
obojene i fotografirane. @ivotinje su primale slijede}u terapiju: destiliranom vodom (kontrole) ili BPC 157 u konc.
R. Lazi} et al.: BPC 157 Heals Corneal Epithelial Defects, Coll. Antropol. 29 (2005) 1: 321–325
324
U:\coll-antropolo\coll-antro-1-2005\lazic.vp
24. lipanj 2005 10:08:59
Plate: 1 of 1
Color profile: Disabled
Black  150 lpi at 45 degrees
2 pg/ml, 2 ng/ml, 2 µg/ml u dozi od 2 kapi po oku odmah nakon ozlijede, svakih 8 sati sve do 40 sati (0, 8, 16, 24, 32, 40
h). Lezije su fotografirane prije aplikacije i prije `rtvovanja (nakon 48 h). Veli~ina ro`ni~nog defekta analizirana je
specijalnim programom. U kontrola je uo~ena polagana epitelizacija kroz 48-satni period. Oporavak je bio znantno ubr-
zan u o~ima koje su primale lokalnu terapiju s BPC 157 u µg- ili ng koncentracijama (p < 0,05). Za razliku od kontrola,
lezije su u cijelosti epitelizirale nakon 40 h (µg) ili 48 h (ng) nakon ozlijede. Ovisno o dozi, BPC 157 pokazao se
efektivan u stimuliranju epitelizacije ro`nice u {takora.
R. Lazi} et al.: BPC 157 Heals Corneal Epithelial Defects, Coll. Antropol. 29 (2005) 1: 321–325
325
U:\coll-antropolo\coll-antro-1-2005\lazic.vp
17. lipanj 2005 10:26:18
Color profile: Disabled
Composite  150 lpi at 45 degrees
